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 Environmental Chemical Exposures
 a d Disturbances of Heme Synth is
 William E. Daniell,1 Henry L. Stockbridge,2 Robert F. Labbe,3
 James S. Woods,1 Karl E. Anderson,4 D. Montgomery
 Bissell,5 Joseph R. Bloomer,6 Ralph D. Ellefso ,7 Michael R.
 Moore,8 Claus A. Pierach,9 William E. Schreiber,10
 Ayalew Tefferi,11 and Gary M. Franklin2
 Porphyrias are relatively uncommon inherited or acquired disorders in which clinical
 manifestations are attributable to a disturbance f heme synthesis (porphyrin metabolism),
 usually in association with endogenous or exogenous stressors. Porphyrias are characterized by
 elevations of heme precursors in blo d, u ine, and/or s ool. A number of chemicals, particularly
 metals and halogenat d hydrocarb ns, induce distu bances of heme synt sis in experimental
 animals. Certain chemicals have also been linked to porphyria or porphyrinuria in hu a s,
 generally involving chronic industrial exposures or environmental exposures much higher than
 those usually encounte ed. A oteworthy example is the Turkish epidemic of porphyria cu anea
 arda produced by accidental ingestion of wheat treat d with the fungicide hexachlorobenz ne.
 Measurements of excreted heme precurs rs have the potential to serve as biological ma kers for
 harmful bu  preclinical eff cts of e tain chemical exposures; this potential warrants further
 research and applied field studies. It has been hypothesized tha  several o herwise unexplained
 che i al-associated illnesses, such as multiple chemical sensitivity syndrome, may re resent
 mild chronic cases of porphyria or other acquired abnormalities in heme synthesis. This review
 concludes that, although it is reas nable to consider such hypot ses, there is currently no
 vincing evidence that these illnesses are mediat d by a disturbance of heme synthesis; it is
 premature or unfounded to base clinical management on such explanations unless laboratory
 data are diagnostic for porphyria. This review discusses the limitations of laboratory measures of
 heme synthesis, and diagnostic guidelin s are provided to assis  in evaluating the symptomatic
 individual suspected of having a porphyria. - Environ Health Perspect 105(Suppl 1):37-53 (1997)
 Key words: biological markers, diagnosis, environmental exposure, hexachlorobenzene,
 laborato y, lead, metals, multiple chemical sensitivity, occupational exposure, porphyria,
 porphyrins
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 Abbreviations used: ADP, ALA-D deficiency porphyria; AIP, acute intermittent porphyria; ALA, &aminole-
 vulinic acid; ALA-D, LA dehydratase; CEP, congenital erythropoietic po phyria; CHP, chronic hepatic porphyria;
 Copro-O, coproporphyrinogen oxidase; 2,4-D, 2,4-dichlorophenoxyacetic acid; EPP, erythropoietic p otopor-
 phy ia; FEP, free eryth ocyt  protoporphyrin; HCB, hexachlorobenzen ; HCP, hereditary coproporphyria; HEP,
 hepatoerythropoietic p rphyria; MCS, multiple chemi al sensitivity (syndrome); PBB(s), lybrominated
 biphenyl(s); PBG, porphobilinogen; PCB(s), polychlorinated biphenyl(s); PCT, po phyria cutanea tarda; 2,4,5-T,
 2,4,5-trichlorophenoxyacetic acid; TCDD(s), tetrachlorodibenzodioxin( ); Uro-D, uroporphyri ogen decarboxy-
 lase; VP, variegate porphyria; ZPP, zinc protoporphyrin.
 Introduction
 Porphyrias are inherited or acquired
 metabolic disorders in which the clinical
 manifestations are attributable to char-
 acteristic patterns of overproduction of
 specific heme precursors and their accumu-
 lation in certain tissues as a consequence of
 decreased activity of a specific enzyme(s) in
 the heme synthesis pathway, usually in
 association with stimulation of the initial
 stage of the heme-forming system by endo-
 genou  or exogenous stresso s. When clini-
 cally active, and in some cases even when
 latent or in clinical remissi n, porphyrias
 induce high levels of heme precursors in
 blood, urine, and/or stool.
 Porphyrias are relatively uncommon
 conditions but are probably underrecog-
 nized. The prevalence of genetic predispo-
 sition to porphyria probably has been
 underestimated in the general population
 because of the limited availability of clinical
 tests for specific heme-synthesis enzymes
 and because prevalence studies generally
 have focused more on family members of
 affected individuals and less on the general
 population. The symptomatic manifesta-
 tions of porphyria, particularly the noncuta-
 neous manifestations, are often nonspecific
 and may not be accompanied by supporting
 physical signs. Most clinicians encounter
 and recognize few if any cases of porphyria
 in the course of their careers, and in gen-
 eral their levels of suspicion for these con-
 ditions are low; yet diagnosis of porphyria
 is critically dependent on the clinician first
 suspecting it as a possible cause of a patient's
 symptoms and then ordering the specific
 essential diagnostic ests.
 Some of the inherited porphyrias occur
 commonly as toxicogenetic conditions,
 where the genetically acquired trait is clini-
 cally latent until clinical manife tations of
 porphyria are triggered idiosyncratically by
 exposure to certain therapeutic drugs, chem-
 icals, or alcohol. Porphyria also can occur
 as an acquired toxin-induced condition,
 where biochemical and clinical manifesta-
 tions of the porphyria are actually caused
 by exposure to certain chemicals in indi-
 viduals with no evident genetic predisposi-
 tion. In addition, certain chemicals can
 produce disturbances of heme synthesis
 that are associated with alterations of
 subcellular structure and functions and
 characteristic changes in patterns of heme-
 precursor excretion. These measurable
 changes offer potential biological markers
 for detecting h rmful effects of specific
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 chemical exposures while their biological
 effects are still preclinical and potentially
 reversible. Most clinicians, however,
 including specialists in occupational and
 environmental medicine, are relatively
 uninformed about these phenomena.
 It has recently been proposed that a
 variety of chemical-associated illnesses for
 which there are no widely accepted specific
 diagnostic tests or etiologic explanations-
 such as multiple chemical sensitivity
 (MCS) syndrome, Persian Gulf War ill-
 nesses, conditions associated with silicone
 breast implants, and various fatigue syn-
 dromes-may represent either mild chronic
 cases of porphyria, or, at least in part, man-
 ifestations of acquired abnormalities in
 heme synthesis. Although diagnoses of por-
 phyria and porphyrialike conditions in
 such cases are commonly dismissed by
 other clinicians and researchers, these diag-
 noses are increasingly put forth as objective
 justification for recommending major
 lifestyle modifications and therapeutic
 interventions in individual cases.
 This article reviews pertinent medical
 and scientific literature in order to provide
 a foundation to address current issues
 related to environmental chemical expo-
 sures and possible disturbances of heme syn-
 thesis. The first three sections of this review
 provide necessary background information
 about heme synthesis and the classification
 and biochemistry of porphyria; more
 detailed information is available in the
 cited general references (1-10).
 Heme Synthesis
 Heme is a biological compound that, when
 combined with certain proteins, plays a
 central role in a variety of vital physiologic
 functions, including oxygen binding and
 transport (hemoglobin and myoglobin), res-
 piratory electron transport (cytochromes a,
 a3, b1, c, and cl), activation and decomposi-
 tion of hydrogen peroxide (catalase and per-
 oxidase), and other oxidation-reduction
 functions (cytochromes P450 and b5). Heme
 synthesis, which is often also referred to as
 porphyrin metabolism, occurs in all human
 cells. It is especially productive in the eryth-
 ropoietic cells in bone marrow, where
 nearly all of the heme is used for hemoglo-
 bin, and in the liver, where the heme is
 primarily needed in cytochrome P450.
 Heme, or iron-protoporphyrin IX, is
 produced by a metabolic pathway that
 involves eight enzyme-controlled steps (see
 below and Figure 1).
 *Succinyl CoA and glycine are com-
 bined to form 6-aminolevulinic acid
 Cytoplasm
 6-Aminolevulinic acid
 l2
 Porphobilinogen
 3
 Hydroxymethylbilane
 4c I4
 Uroporphyrinogen I Uroporphyrinogen III
 5Copopophynogen 5b
 Coproporphyrinogen I Coproporphyrinogen III
 Figure 1. Heme Biosynthesis Pathway. Numbers designate individual enzyme-catalyzed steps of heme biosynthe-
 sis. Enzyme name, step 1, ALA synthase; step 2, ALA dehydratase; step 3, PBG deaminase (uroporphyrinogen syn-
 thase); step 4, uroporphyrinogen-lll cosynthase; step 5, uroporphyrinogen decarboxylase; step 6,
 coproporphyrinogen oxidase; step 7, protoporphyrinogen oxidase; step 8, ferrochelatase. "ALA is synthesized
 within mitochondria in step 1 and then traverses to cytoplasm, where step 2 occurs. Coproporphyrinogen III is syn-
 thesized in cytoplasm in step 5 and then traverses into mitochondria, where step 6 occurs. blntermediate precur-
 sors not shown for step 5 (7-, 6-, and 5-carboxyl porphyrinogens) or step 6 (3-carboxyl porphyrinogen). CAlternative
 pathway at step 4 (hydroxymethylbilane to uroporphyrinogen I) is not enzymatically catalyzed.
 (ALA), an amino acid committed
 exclusively to heme synthesis.
 * Two ALA molecules are condensed to
 form porphobilinogen (PBG), a mono-
 pyrrole.
 * Four PBG molecules are polymerized
 to form the linear tetrapyrrole hydroxy-
 methylbilane.
 * Hydroxymethylbilane is converted
 enzymatically to the cyclic tetrapyrrole
 uroporphyrinogen III (or nonenzymati-
 cally to an isomer, uroporphyrinogen I,
 which does not act as an intermediate
 in heme synthesis).
 * Sequential decarboxylations produce
 a series of 7-, 6-, and 5-carboxyl pro-
 phyrinogens and then coproporphy-
 rinogen III.
 * Further sequential decarboxylations
 produce 3-carboxyl porphyrinogen and
 then protoporphyrinogen IX.
 * Protoporphyrinogen IX undergoes oxi-
 dation to protoporphyrin IX.
 * Protoporphyrin IX is chelated with fer-
 rous iron to produce heme.
 Heme and protoporphyrin IX are the
 only directly formed intermediates in the
 heme synthesis pathway that are actual
 porphyrins rather than porphyrinogens.
 However, porphyrinogens are readily oxi-
 dized to the respective porphyrin forms,
 particularly when removed from the body.
 Most laboratory assays measure and report
 porphyrinogens in porphyrin form. For the
 convenience of a summary term, we use the
 term heme precursors loosely to include
 measured porphyrin forms of porphyrino-
 gens as well as the true intermediates of
 heme synthesis.
 Classification of Porphyrias
 Most types of porphyria are known to
 occur only as inherited conditions; how-
 ever, one type of porphyria [porphyria
 cutanea tarda (PCT)] is known to occur in
 either an acquired or an inherited manner.
 The inherited porphyrias are attributable
 to an autosomal dominant or autosomal
 recessive genetic defect affecting a single
 enzyme in the heme synthesis pathway but
 rarely are attributable to coexistent defects
 separately affecting two different heme-
 synthesis enzymes.
 Porphyrias historically have been classi-
 fied in various ways (see Table 1), includ-
 ing: specific enzyme(s) principally involved;
 nature of underlying inherited defect, if any
 (autosomal dominant, autosomal recessive,
 acquired); principal origin(s) of the excess
 heme precursors (hepatic, erythropoietic,
 mixed); usual temporal pattern of sympto-
 matic manifestations (acute or chronic);
 and principal nature of symptomatic
 manifestations (neurologic, neurocuta-
 neous, cutaneous). These classifications
 overlap and are not mutually exclusive.
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 Table 1. Classification of porphyrias and lead intoxication.
 Principal origin of
 excess heme precursors
 Erythropoietic Hepatic
 Symptom pattern
 Acute Chronic
 Symptoms
 Neurologic Cutaneous
 Porphyrias
 LADiP :AR 2 l Unknown U nknown t
 IP AD 3 + + +
 CSEP AR I : + : - l - : A
 PCT AD or 5 + +
 cq . :::A : i red 5 i i e- \ ' ::1
 HEP R 5 + + +
 i P-:P AD :6 : I ::::::: .. 6 : 1::-.-;;;......
 V  AD 7 + + + + +
 EPP A ::: 8 . + :::
 Lead intoxication Acquired 2,6,8b + + + +
 Abbreviations: AD, autosomal dominant inheritance; AR, autosomal recessive inheritance; +, usually present; +, variably present. aHeme synthesis enzyme designated by step
 number (see Figure 1). bThere is apparent interference by lead with these steps. In cases of lead intoxication, there may be mechanisms other than lead inhibition of the
 enzymes at steps 6 and 8 [Rossi (1 1)].
 Porphyrias with Neurologic
 Manifestations
 Symptoms in the neurologic porphyrias
 [ALA dehydratase (ALA-D) deficiency por-
 phyria (ADP) and acute intermittent por-
 phyria (AIP)] and noncutaneous symptoms
 in the neurocutaneous porphyrias [heredi-
 tary coproporphyria (HCP) and variegate
 porphyria (VP)] tend to occur in intermit-
 tent acute attacks, with variable degrees of
 symptom presence between attacks. Clinical
 onset of the neurologic and neurocuta-
 neous porphyrias usually occurs in postpu-
 bertal adolescents or adults; attacks are
 more common in women than men. Only
 six cases of ADP have been reported (7).
 AIP is one of the more prevalent types of
 clinically manifested porphyria, at least in
 the United States.
 All the neurologic and neurocutaneous
 porphyrias (except ADP) are classified as
 hepatic porphyrias because the liver is a
 principal site in which the enzyme defi-
 ciency manifests itself biochemically. Liver
 function abnormalities are common but are
 generally mild or moderate (12). Several
 studies have indicated that individuals with
 AIP are at risk for developing hepatocellular
 carcinoma (13-15). The principal site of
 enzyme expression has not been identified
 clearly for the small number of patients
 reported to have ADP.
 The neurologic manifestations of acute
 attacks are indistinguishable for the various
 neurologic and neurocutaneous porphyrias,
 and these conditions are differentiated by
 biochemical or genetic testing. The princi-
 pal manifestations reflect broad dysfunction
 of the nervous system. Frequent symptoms
 include: abdominal pain, constipation, nau-
 sea, vomiting, tachycardia, hypertension,
 fever (i.e., autonomic nervous system);
 weakness, back and extremity pains,
 localized or extensive pareses or paralysis,
 par sthesias, hypoesthesias (i.e., peripheral
 nervous system); and psychiatric or behav-
ioral symptoms (i.e., central nervous
system). Hyponatremia may reflect inap-
 propriate secretion of antidiuretic hormone
 (i.e., hypothalamus). The intensity of
 sympt ms, part cula ly pain, can be severe;
 associated physical signs, however, are
 commo ly either absent or disproportion-
 ate y less intense. Symptoms are generally
less severe in HCP (7).
Most individuals who possess the
 genetic defect associated with one of the
neurologic or neurocutaneous porphyrias
sh w no recognizable clinical manifesta-
 ions of po phyria throughout their lives.
 Only about 10% of individuals genetically
 predisposed to AIP r VP, and probably no
 more than one-third of those predisposed
 to HCP, ver de lop the characteristic
 attacks of acute symptoms (4,7,16-18). If
 and when symptoms develop in a geneti-
 cally predisposed individual, the initial
 onset and any subsequent recurrences often
 are linked to precipitating factors such as
 us  of a therapeutic drug, exposure to a
 provocative chemical, alcohol consump-
 tion, t bacco smok ng, an infection, the
 enstrual cycle, or fasting (1).
 The frequency and severity of symptom
 attacks vary widely both among and within
 individuals. In most cases, symptom
 attacks have discernible onsets, are charac-
 terized by moderate or severe pain, last sev-
 eral days or long r (up to weeks or months),
and are f llowed or separated by periods
 of clinical remission. Attacks are usually
 recurrent but not ecessarily (18). Some
 manifestations of acute attacks can persist
 after the other clinical and biochemical
 manifestations subside or resolve; this is
 particularly true for peripheral motor neu-
 ropathy, which can take up to 1 year to
 resolve or can become permanent (19,20).
 Permanent neurological deficits are not
 nec ssarily accompanied by heme precursor
 abnormalities when a patient's porphyria is
 otherwise in remission.
 In contras  to the typical cute presen-
 tation, sympt ms in some cases can occur
 nondistinctly in time an /or be relatively
 mild and some symptoms, particularly pain
 or psychiatric manifestations, can become
 chronic, oft n with variable severity over
 time (7,9,21). Given such complex presen-
 tations as well s th  frequent aucity of
 physica  signs, the diagnosis of porphyria
 c n be delayed or missed entirely. Accord-
 ingly, screening surveys of psychiatric
 inpatient  have reported a relatively high
 preval nce o  individuals with reviously
 unrec gnized porphyria (22-24). One
 recent study, however, found no significant
 increase in major psychiatric illness among
 344 co secut ve patients with AIP (25).
 Porphyrias with Neurologic and/or
 Cutaneous Manifestations
 The neurocutaneous p rphyrias, VP and
 HCP, can manifest cutaneous lesions as
 well as acute oncutaneous symptom
 attacks. One review of 110 cases of HCP
reported that 30% experie ced acute pho-
 tosensitive responses, usually in association
 with acute symptom attacks (16). In con-
 rast, acute photosensitivity is not common
 in VP; the cutaneous lesions tend to be
 chronic and they occur more often in indi-
 viduals who do no  have acute symptom
 at acks th n in those who do (26,27). The
 cutaneous lesions of VP are parti ularly
 common in hot climates-about 75% in a
 Environmental Health Perspectives * Vol 105, Supplement 1 * February 1997
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 series of South African patients with clini-
 cally active VP (27). The cutaneous lesions
 of VP and chronic cutaneous lesions of
 HCP cannot be distinguished clinically or
 histologically from PCT (see below).
 Porphyrias with Cutaneous
 Manifestations
 The cutaneous porphyrias include all the
 porphyrias classified as erythropoietic [con-
 genital erythropoietic porphyria (CEP),
 hepatoerythropoietic porphyria (HEP), and
 erythropoietic protoporphyria (EPP)] plus
 the nonerythropoietic porphyria PCT. The
 hereditary and acquired forms of PCT usu-
 ally manifest first in adulthood, whereas
 clinical onset of the erythropoietic porphyr-
 ias usually occurs in infancy or childhood.
 There is no gender predilection in PCT,
 although in the past it has tended to occur
 more often in men. The erythropoietic por-
 phyrias are relatively uncommon: fewer
 than 200 cases of CEP and fewer than 20
 cases of HEP have been reported (7,28,29).
 The cutaneous manifestations of CEP,
 PCT, and HEP (and VP and HCP) can be
 difficult to distinguish on the basis of clini-
 cal or histologic appearance, although the
 lesions of the autosomal recessive condi-
 tions, CEP and HEP, are usually more
 severe. Cutaneous manifestations include:
 skin fragility, vesiculobullous skin erup-
 tions evolving into crusted ulcers, and
 residual hyperpigmentation or scarring,
 primarily occurring in sun-exposed areas of
 the body (7,30). Facial hypertrichosis is
 also common. The pattern of EPP differs
 substantially and is generally less severe
 than in the other cutaneous porphyrias; it
 is characterized by acute photosensitivity
 manifesting as pain, pruritus, and erythema
 with exposure as short as minutes, and gen-
 erally without vesiculobullous lesions or
 scarring unless sun exposure is prolonged
 (30,31). Liver injury is usually not found
 with the cutaneous porphyrias other than
 in some patients with EPP, in which case it
 can be severe and potentially fatal.
 Porphyria Cutanea Tarda
 Porphyria cutanea tarda is one of the most
 prevalent types of porphyria; it occurs
 more often as a sporadic condition than as
 a familial inherited condition. The genetic
 defect associated with the familial form is
 inherited in autosomal-dominant manner.
 Hepatic uroporphyrinogen decarboxylase
 (Uro-D) activity is decreased in all forms of
 PCT; erythrocyte Uro-D activity, however,
 is normal in the sporadic form but is
 decreased in all but a small subgroup of
fam lial cases (32). The sporadic and famil-
 ial forms of PCT usually occur in associa-
 tion with exogenous factors such as alcohol,
al estrogens, iron, and certain chemicals,
 or with certain medical conditions, particu-
 larly liver diseases; both are successfully
 treated in the same manner (2,7). Familial
 PCT, therefore, can be regarded at least
 partially as an acquired condition in which
 the inherited enzyme deficiency may only
 increase an individual's susceptibility to
 disease (33).
 PCT is usually associated with some
 d gree of liver abnormality (2,3,8). Liver
 function tests are nearly always abnormal to
 some degree. Moderate siderosis and vari-
 ous degrees of fibrosis or necrosis are often
 found upon biopsy, and cirrhosis develops
 in a small proportion of patients. It is com-
 mon for PCT to develop in individuals
 with preexisting liver disease of a variety of
 types, particularly alcoholic liver disease or
 chronic hepatitis C (34-38). Patients with
 chronic liver disease also can develop mild
 or moderate degrees of porphyrinuria
 (increased urine porphyrins) in biochemical
 patterns that can be consistent with PCT
 but without associated cutaneous lesions
 (see "Chronic Hepatic Porphyria") (2,39).
 Patients with PCT are reported to be at risk
 for developing hepatocellular carcinoma
 (13,40-42); conversely, some benign or
 malignant liver tumors can overproduce
 uroporphyrin and induce PCT (43-45).
 Biochemistry of Porphyrias
 Deficient activity of a heme-synthesis
 enzyme results in accumulation of the
 heme precursors proximal to the defi-
 ciency, although overall production of
 heme is generally adequate (1-10,46). The
 water solubility of the heme precursors
 decreases progressively with successive steps
 of heme synthesis. Excess protoporphyrin
 is excreted exclusively in stool; copropor-
 phyrinogen, uroporphyrinogen, and the 7-,
 6-, and 5-carboxyl porphyrinogens are
 excreted in both urine and stool, and ALA
 and PBG are excreted predominantly in
 urine. Porphyrins in stool undergo varying
 degrees of transformation by normal
 enteric bacteria (47,48). When a heme-
 synthesis enzyme deficiency is expressed
 more in one tissue than another, heme pre-
 cursors that accumulate in one tissue can
 be transported in blood to other tissues,
 with subsequent conversion to later inter-
 mediates in the heme synthesis pathway;
 experimental ALA loading, for example,
 leads to prompt coproporphyrinuria in
 humans (49-51).
 In general, the neurologic (and neuro-
 cutaneous) porphyrias are characterized by
 excessive excretion of the porphyrinogen
 precursors, ALA and PBG, in urine; the
 cutaneous (and neurocutaneous) porphyr-
 ias are characterized by the accumulation
 of porphyrins in blood and excessive excre-
 tion of porphyrins in urine and/or stool
 (46,52-54). Individual types of porphyria
 can be differentiated by the pattern of
 heme precursors (i.e., the absolute values
 and the ratios to each other) in a patient's
 urine, blood, and stool, if collected either
 during or soon after attacks of neurologic
 symptoms or while porphyric skin lesions
 are actively manifested. Excretion of ALA
 and PBG in urine usually normalizes
 within several weeks following an acute
 attack in VP or HCP (16,26,27); in AIP,
 urine excretion commonly subsides but
 might not completely normalize during
 remissions (19,20). Compared to an acute
 attack, urine porphyrinogen precursors
 (i.e., ALA and PBG) may be lower in VP
 when solely cutaneous lesions are present,
 but urine porphyrins are still increased to
 diagnostic levels (27). Porphyrins are
 always increased in the plasma of patients
 with active cutaneous lesions (10).
 When an individual has symptomatic
 manifestations of a porphyria (i.e., when
 clinically active and not latent or in remis-
 sion), the level of the most excessively
 excreted heme precursor is typically at least
 several-fold greater than the values reported
 for the upper limit of normal. In reports
 describing the neurologic porphyrias, for
 example, urine ALA and PBG in AIP
 increased acutely to 8 to 150 and 30 to 200
 mg/day, respectively (normal upper limits, 3
 to 7.5 mg/day, depending on the labora-
 tory) (7,20,26,55-57); and in ADP, urine
 ALA was markedly elevated and urine and
 erythrocyte porphyrins were elevated up to
 100 times (7,10). In reports of the neurocu-
 taneous porphyrias, urine coproporphyrin
 in HCP increased acutely to 4 to 190 times
 normal (16,58). In VP, one small case series
 reported the lowest values of urine ALA,
 PBG, uroporphyrin, and coproporphyrin in
 acute attacks to be 9, 12, 190, and 27 times
 the mean control values, respectively (26),
 which was consistent with the higher aver-
 age values reported in a larger series (27). In
 reports of the cutaneous porphyrias, urine
 uroporphyrin in PCT increased to about
 10 to 375 times normal in over 300 reported
 cases (except in one case (59), where a
 single value was within normal range)
 (60-70), and in EPP, reported erythrocyte
 protoporphyrin values ranged from 2.4 to
 Environmental Health Perspectives * Vol 105, Supplement 1 * February 1997 40
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 90 times normal (31,65,71), with the
 exception of a single patient in whom it
 was elevated by only a factor of 1.4 (31).
 Finally, in reports of the less common
 (autosomal-recessive) cutaneous porphy-
 rias, urine porphyrins in CEP were 20 to
 60 times normal (7) and in HEP, urine
 uroporphyrin increased by at least 20-fold
 and erythrocyte porphyrins increased by
 5- to 10-fold (28,29,72). Plasma porphy-
 rin concentrations are markedly increased
 when there are active skin lesions due to
 any cutaneous porphyria (10).
 Secondary Porphyrinuria
 Some of the tests used to diagnose the
 porphyrias are nonspecific and are abnor-
 mal in a variety of circumstances other than
 the porphyrias. Porphyrinuria can be
 caused by porphyrias, by a number of other
 medical conditions, especially those affect-
 ing the liver or bone marrow, and by a vari-
 ety of exogenous factors such as alcohol and
 certain drugs and chemicals that disturb
 heme synthesis or stress heme-dependent
 metabolism (1,73-76). The term sec-
 ondary porphyrinuria is commonly applied
 to the porphyrinuria occurring with condi-
 tions and factors lacking a primary enzyme
 defect in heme synthesis. It usually involves
 mild or moderate coproporphyrinuria, with
 no or little excess uroporphyrin in urine,
 and is also often called coproporphyrinuria
 or secondary coproporphyrinuria.
 The detection of porphyrinuria has
 potential utility as a biological indicator of
 exposure to chemicals with porphyrinogenic
 properties and as a staging measure for sub-
 clinical development and progression of
 chronic hepatic porphyria (see "Chronic
 Hepatic Porphyria and Environmental
 Chemicals and Effects on Measures of
 Heme Synthesis"). However, with the
 noteworthy exception of lead poisoning
 (see "Environmental Chemicals and Effects
 on Measures of Heme Synthesis"), the por-
 phyrin excess in secondary porphyrinuria
 has no recognized clinically detectable
 consequences of its own. Most reviewers
 attribute symptoms associated with sec-
 ondary porphyrinuria (other than lead poi-
 soning) to the condition or agent causing
 the porphyrinuria or to an unrelated cause,
 not to a disturbance in heme synthesis
 (2,3,10,75,77-81). Still, although the
 porphyrinuria itself may be benign, an
 associated medical condition may be far
 from benign.
 Accumulation or excessive excretion of
 heme precursors does not necessarily mean
 there is a deficiency of a heme pathway
 enzyme(s); other possible mechanisms
 exist. Increased erythropoiesis can produce
 increases in urine coproporphyrin, as
 de onstrated by induced anemia in experi-
 mental animals (82). Coproporphyrin nor-
 mally is excreted in bile and in urine, and
impaired biliary excretion in hepatobiliary
disease leads to increased coproporphyrin
 excretion in urine (83). Stimulation of
 hepatic heme synthesis (e.g., by certain
 drugs) in the absence of deficiency of any
 heme-synthesis enzymes can lead to
 increased coproporphyrin excretion. The
 kidney (primarily the epithelium of the
 proximal tubules) has been identified as a
 major source of porphyrins (primarily
 coproporphyrin) in the urine of normal
 and porphyric individuals as well as lead-
 and mercury-poisoned individuals (84-87).
 It is conceivable that toxic effects on renal
 tubular function could lead to increased
 urinary loss of porphyrins along with other
 substances handled by renal tubules without
 inhibition of heme synthesis.
 Chronic Hepatic Porphyria
 Based on clinical experience (77,88), and
 with supporting evidence from animal
 experiments (89), Doss (39,75,90) has
 described the potential for chronic nonspe-
 cific disturbances in hepatic heme synthesis
 to make a transition from secondary copro-
 porphyrinuria and progress through several
 clinically latent stages of chronic hepatic
 porphyria [(CHP) Types A, B, and C] to
 PCT (CHP Type D). Each stage in the
 Doss model (75,88) is differentiable by
 urine porphyrin quantities and patterns
 (i.e., initial accumulation of uroporphyrin
 and later heptacarboxyl porphyrin in the
 liver), progressively greater degrees of sub-
 clinical liver injury, and ultimately the
 occurrence of cutaneous lesions. The tran-
 sition from secondary coproporphyrinuria
 to CHP requires either a genetic defect or
 toxic inhibition of Uro-D activity in the
 liver, generally in combination with liver
 disease and precipitating factors such as
 alcohol or estrogens.
 The Doss model, however, is not uni-
f rmly accepted as valid. The evidence in
 humans for the Doss model comes from
 cross-sectional studies of patient populations,
 not longitudinal studies (77,88). There are
 no well-documented cases of individual
 patients actually progressing through CHP
 Types A, B, and C to PCT, and it has not
 been demonstrated that mild degrees of
 porphyrinuria, particularly coproporphy-
 rinuria, predict the potential for an indi-
 vidual to develop PCT. The early stages in
 the CHP model are characterized primarily
 by coproporphyrinuria, which can occur
 nonspecifically with liver disease and may
 reflect a separate phenomenon. There is no
 evidence or reason to predict that hepatic
Uro-D deficiency is manifested initially by
 coproporphyrinuria before uroporphyrin-
 uria. In addition, there is evidence that
the kidney may be the primary source of
 coproporphyrin and other porphyrins
excreted in normal urine and may also be a
 major source in certain porphyrias and
toxin-induced porphyrinurias (84,91,92).
 Environmental Chemicals
 and Effects on Measures
 of Heme Synthesis
 In individuals who are genetically predis-
 posed to developing an acute or cutaneous
 porphyria (e.g., inheriting one allele), the
 biochemical and clinical manifestations of
 porphyria can be triggered by a variety of
 exogenous factors including certain chemi-
 cals and therapeutic drugs, alcohol con-
 sumption, tobacco smoking, infections,
 and dietary factors, as well as by certain
 medical conditions and endogenous factors
 such as the menstrual cycle (1). Exposure
 to the sun can trigger cutaneous manifesta-
 tions of porphyria if an excess of por-
 phyrins already exists. Therapeutic drugs
 are particularly well recognized as possible
 precipitants of acute porphyria and current
 lists of drugs classified as unsafe and drugs
 thought to be safe for use in acute porphyr-
 ias are maintained (93-95). Exogenous fac-
 tors can also cause changes in the heme
 ynthesis pathway, even in the absence of
 genetic predisposition; in some cases, these
 acquired changes have been reported to
 cause PCT.
 A number of chemicals, including
 halogenated hydrocarbons and metals, are
 known to be porphyrinogenic (i.e., capable
 of inducing changes in heme synthesis,
 with subsequent overproduction and
 excessive excretion of heme precursors) in
 experimental animals, generally with expo-
 sure by ingestion and with doses much
 greater than the range of human experience
 (96-98). In addition to possible inter-
 species differences, the differences in dose
 and pattern of exposure limit the ability to
 extrapolate from experimental animal
 studies in order to assess the potential risks
 of specific chemicals for humans. Unfortu-
 nately, there has been only limited system-
 atic study of the subject in humans. In
 humans, with the noteworthy exceptions of
 porphyria caused by hexachlorobenzene
 (HCB) ingestion and the porphyrinuria
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 caused by lead, reports of porphyria or
 porphyrinuria attributable to chemical
 exposures have been infrequent. The
 reported findings have generally been
 linked to chronic industrial exposures,
 industrial accidents, or environmental
 exposures that were much higher than
 usually encountered.
 Hexachlorobenzene
 The most noteworthy incident of chemical-
 induced porphyria in humans occurred
 in Turkey during the late 1950s, when
 approximately 3000 cases of PCT devel-
 oped from the ingestion of seed wheat
 treated with fungicides containing about
 10% HCB (99-106). The wheat was
 treated in anticipation of use for planting
 but was instead used for human consump-
 tion. The syndrome commonly consisted
 of weight loss, muscle wasting, weakness,
 hepatomegaly, thyromegaly, arthritic
 changes, gross porphyrinuria, hypertri-
 chosis, and photosensitive dermopathy
 (99,102). The dermopathy was usually
 hyperpigmented and had vesiculobullous
 lesions that eventually ulcerated, were com-
 monly complicated by infections, and left
 depigmented scars and often disfiguring
 contractures. Active skin lesions tended to
 abate within a month after HCB exposure
 ended but often recurred subsequently in
 summer months, even in the absence of
 any new exposure to HCB. Children were
 affected disproportionately more than
 adults. Some reports noted the absence of
 abdominal crises, mental disturbances, and
 other neurologic complications (99,100);
 others noted the presence of abdominal colic
 and muscle weakness during the acute phase
 (102). Follow-up studies up to 30 years
 later reported that a majority of the patients
 studied had cutaneous residua, arthritic
 deformities, thyromegaly (particularly in
 women), and neurologic manifestations
 including weakness, paresthesias, and sensory
 shading; smaller proportions of patients
 had myotonia or cogwheel rigidity without
 other extrapyramidal signs (103-106).
 Administration of HCB to experimen-
 tal animals causes a deficiency of hepatic
 Uro-D and a pattern of porphyrin accumu-
 lation closely resembling that in human
 PCT (89,107-111).
 Dioxin
 Laboratory experiments have demonstrated
 that tetrachlorodibenzodioxins (dioxin(s)
 or TCDDs) in high ingested doses are por-
 phyrinogenic in rodents (112,113), but the
 evidence in humans is mixed. The strongest
 human evidence is from two workplace
 studies. In 1964, a study at a New Jersey
 chemical plant that produced the herbi-
 cides 2,4-dichlorophenoxyacetic acid
 (2,4-D) and 2,4,5-trichlorophenoxyacetic
 acid (2,4,5-T) described two workers with
 PCT and another with possible PCT, and
 also reported that urine uroporphyrins
 were positive in 8 of 26 other workers
 (114). Most workers studied had chlo-
 racne, prototypically caused by dioxin,
 which was then a frequent contaminant
 of 2,4,5-T production. Another study of
 55 workers arriving at a hospital from a
 Czechoslovakian herbicide manufacturing
 plant found a high prevalence of chloracne,
 11 workers with PCT, and slightly
 increased urine uroporphyrin (< 100 pg/
 24 hr; reference range not stated) in 21%
 of those tested (115). One worker in a
 TCDD-contaminated workplace developed
 PCT, sarcoma, and probable chloracne; the
 combined occurrence of these rare condi-
 tions suggested an etiological relation to
 the TCDD exposure (116,117). Other
 workplace studies, however, have been less
 demonstrative. A later study at the same
 New Jersey plant found no active cases of
 PCT and no workers with abnormal urine
 excretion of heme precursors except one
 worker who formerly had severe PCT
(118). Maintenance workers, who had the
 highest chemical exposures, were found to
 have higher average urine coproporphyrin
 levels than other workers, but their individ-
 ual levels were all within normal limits.
 Two separate later studies of herbicide pro-
 duction plants (one of which included the
 New Jersey plant mentioned above) (119)
 w re both negative (120).
 Limited evidence is also available from
 community studies. An explosion at a
 chemical plant in Seveso, Italy, in 1976
 contaminated the surrounding environ-
 ment with TCDDs. Two related individ-
 uals who were found to have a preexisting
 familial defect in Uro-D were reported to
 manifest PCT after the explosion without
 another evident precipitating factor (121).
 Among 60 Seveso residents from other
 families, 8 were reported to have secondary
 coproporphyrinuria and 5 had a transition
 constellation to CHP Type A (121) (see
 "Chronic Hepatic Porphyria"). Another
 study, of 115 Seveso residents, found that
 84% had urine porphyrin patterns consis-
 tent with coproporphyrinuria or CHP
 Type A, with the greatest prevalence and
 degree of abnormality in residents from
 areas of highest contamination (122). A
 later study, however, reported chloracne
 but no PCT attributable to TCDDs
 among Seveso children and adolescents
 (123,124). In two studies of Missouri
 communities where TCDD-contaminated
 waste oil had been sprayed for dust control
 over several years, there were no cases of
 PCT, but one study found significantly
 higher mean uroporphyrin levels in urine
 and higher prevalence of elevated urine
 uroporphyrin values (> 13 pg/g creatinine
 (cre) in 16%, vs 7% controls) among
 154 residents of a contaminated mobile
home park compared to matched control
 subjects (125,126).
 Other Halogenated Hydrocarbons
 A number of halogenated hydrocarbons
 have been demonstrated experimentally to
 be porphyrinogenic in exposed animals or
 in in vitro tests; these are well summarized
 in Strik et al. (96) and Marks (97) and
 will not be described in this review. The
 reported human experience is less exten-
 sive. Haberman et al. (127) mentioned
 that a case of PCT manifested itself soon
 after agricultural application of DDT.
 Lynch et al. (128) reported a case of PCT
 in association with hepatitis, which was
 attributed to chronic toxic exposure and
 presumed to be a polychlorinated phenol
 unintentionially synthesized on a regular
 basis by mixing cleaning agents containing
 benzylchlorophenol and sodium hypochlo-
 rite. A worker with severe acute methyl
 chloride intoxication had marked increase
 in urine and fecal excretion of copropor-
 phyrin but not uroporphyrin or protopor-
 phyrin; the coproporphyrinuria decreased
 in association with clinical improvement
 (129). Evaluation of 46 workers exposed to
 vinyl chloride in a polyvinyl chloride pro-
 duction process found that 36 had copro-
 porphyrinuria (<820 nmol/24 hr; normal
 (nl) < 130), including 4 who also had
 mildly increased excretion of uroporphyrin
 and heptacarboxyl porphyrin in urine (130).
 A study of Michigan farm families exposed
 o polybrominated biphenyls (PBBs) by
 ingestion of contaminated meat and dairy
 products found that 11 of 126 persons had
 coproporphyrinuria (93-218 pg/liter;
 l< 78), including 4 with mild uroporphy-
 rinuria (29-59 pg/liter; nl<24) (131). Of
 20 individuals in Taiwan, 2 years after poi-
 soning with polychlorinated biphenyls
 (PCBs) in food oil, 3 had elevated uropor-
 phyrin in urine (50-139 pg/liter; controls,
 7-22), 1 of whom, plus 5 others, had ele-
 vated coproporphyrin (61-255 pg/liter;
controls, 2-48) (132). Two separate
 studies of 87 similarly poisoned individuals
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 in Yusho, Japan, about 10 years after the
 event, found no differences in urine por-
 phyrins compared to those of controls and
 identified PCT in 1 person whose history
 was complicated by alcohol use (133,134).
 Total urine porphyrins were not signifi-
 cantly different from those of controls in
 168 chemical plant workers exposed to
 either allylchloride, hexachlorocyclopenta-
 diene, epichlorohydrin, or endrin (135).
 Lead
 Lead absorption, both acute and chronic, is
 well documented to affect heme synthesis
 (11). Lead causes accumulation of zinc
 protoporphyrin (ZPP) in erythrocytes and
 large increases of ALA and coproporphyrin
 in urine. Lead reversibly inhibits ALA-D
 and also appears to interfere with the func-
 tion of coproporphyrinogen oxidase and
 ferrochelatase, possibly by mechanisms
 other than direct enzyme inhibition
 (11,98,136,137). It is conceivable that the
 coproporphyrinuria occurs by the same
 mechanism as in ALA loading of normal
 subjects (Biochemistry of Porphyrias).
 There is evidence that ALA-D poly-
 morphism may influence lead toxicokinet-
 ics. The ALA-D enzyme is comprised of
 eight identical subunits coded by an auto-
 somal gene, at which there are two com-
 mon alleles (138). The ALA-D allele has
 about 80 to 90% prevalence in studied
 European and American population sam-
 ples; the ALA-D2 allele, about 10 to 20%
 (138-142). The three associated pheno-
 types (1-1, 1-2, 2-2) have similar enzyme
 activities in erythrocytes. A number of
 studies have reported that individuals with
 the ALA-D2 allele, particularly the
 homozygous ALA-D 2-2 phenotype, have
 higher blood lead levels on average than
 individuals with the ALA-D 1-1 phenotype
 and comparable lead exposures (142-145).
 The possible mechanism of this reported
 phenomenon is not known, although it has
 been speculated that ALA-D subunits
 coded by the ALA-D2 allele might bind
 lead more efficiently (146). The possible
 clinical relevance also is unclear. Some
 investigators have suggested that ALA-D2
 might render individuals more susceptible
 to lead poisoning (143,145); others have
 suggested that ALA-D2 might protect
 against lead effects (147).
 Lead intoxication is generally classified
 as a secondary porphyrinuria rather than
 an acquired porphyria, although some inves-
 tigators have classified it as a porphyria,
 noting clinical and biochemical similarities
 with the acute porphyrias (see Table 1),
 par icularly ADP (39,148-150). It is not
 known to what degree the manifestations
 f lead poisoning might be attributable, if
 at all, to the associated disturbance in heme
 synthesis apart from the directly neurotoxic
 properties of lead, but there is evidence the
 disturbed heme-forming system may have
 ome contributing role (151,152).
 The reported interaction between lead
 exposure and genetic deficiency of ALA-D
 is noteworthy. ADP is attributable to
 homozygous autosomal-recessive defects
 affecting ALA-D, with near total loss of
 enzyme activity; heterozygous carriers of
 the defect have only partial loss of ALA-D
 activity and usually have no associated
 symptoms (153). However, the heterozy-
gous defect appears to increase the vulnera-
 bility of the individual to the effects of
 exogenous agents such as lead, which
 reduce ALA-D activity. In case reports of
 individuals who had a heterozygous defect
 affecting ALA-D and were exposed to
 lead, the biochemical abnormalities and
 clinical features of illness were consistent
 with lead intoxication but were much
 more severe than expected for their mildly
 elevated blood lead levels (22-43 pg/dl)
 (149,154,155). The prevalence of the het-
 erozygous defect in the general population
 has been estimated variably to be below
 1% (149) or as high as 2% (156).
 Other Metals
 Mercury, arsenic, and other metal exposures
 are also reported to affect heme synthesis in
 humans, although the associated levels of
 porphyrinuria are lower than those seen
 with lead. In a survey of dentists attending
 an annual professional meeting, those who
 were found to have >20 pg/liter mercury in
 spot urine samples also had 2- to 3-fold
 higher levels of coproporphyrin in urine
 (42 ?18 pg/g cre or 74 ? 8 pg/liter;
 mean + SD) than those with no urinary
 mercury (coproporphyrin 28 + 12 pg/g cre
 and 23 ? 6 pg/liter) (87). Urine uropor-
 phyrin excretions did not differ signifi-
 cantly; however, pentacarboxyl porphyrin
 and an atypical porphyrin tentatively iden-
 tified as keto-isocoproporphyrin were sig-
 nificantly elevated in urine. A study of
 random urine samples from 52 workers
 exposed to inorganic and organic mercury
 (median urine mercury about 500 pg/liter)
 found that 23% had elevated copropor-
 phyrin levels (>70 pg/liter and up to 159
 pg/liter) compared to only 3% of control
 subjects (157): Similarly, a study of arsenic-
 exposed smelter workers (urine arsenic
 129 ? 109 pg/g cre in the high-exposure
 group) found more than twice as much
 coproporphyrin (63 ?30, range 18-171,
 pg/g cre) but comparable amounts of
 uroporphyrin in morning urine specimens,
 relative to those of nonexposed control
subjects (coproporphyrin 27 ? 14, range
 2-57, pg/g cre) (158). In another study,
 individuals exposed to arsenic in drinking
 water (urine arsenic mean 65, range 1-130
 pg/liter) were reported to have no signifi-
 cant increase in urine porphyrin levels rela-
 tive to those of a control group, although
 most exposed individuals did have inver-
 sion of the urine coproporphyrin/uropor-
 phyrin ratio (76%, vs 32% of controls)
 (159). Downey (160) reported a case of
 acute intermittent porphyria (laboratory
 esults not presented), with symptoms
 including transient dermatitis, severe
 abdominal pain, diarrhea and vomiting,
 dyscoordination, memory loss, and visual
 hallucinations, all of which developed soon
 after placement of dental prostheses (con-
 taining 76% palladium and 10% copper)
 and resolved "almost immediately" after
 removal of the prostheses.
 Experimental animal and in vitro
 studies have demonstrated a number of
 other metals to be porphyrinogenic, includ-
 ng aluminum, cadmium (with arsenic or
 lead), cobalt, gallium arsenide and others;
 again, these data are summarized in detail
 in other reviews [Marks (97), Woods (98),
 Fowler et al. (161)].
 Other Chemicals
 Bleakley et al. (162) noted, in describing
 levated fecal porphyrins in rats with sub-
 chronic cutaneous exposure to diazinon, "in
 a number of cases seen [of PCT in humans]
 ... a history of contact with pesticides, in
 particular with diazinon." A study of 17
 pulp production workers exposed to hydro-
 gen sulfide and methylmercaptan reported
 reduced activities of ALA synthase, ALA-D,
 and ferrochelatase (relative to reference
 ranges) in the reticulocytes of 8, 1, and 5
 workers, respectively, as well as low erythro-
 cyte protoporphyrin levels in 7 workers
 compared to control values (163). In two
 reported case series of acute porphyria, paints
 and solvents were described as triggers of
 acute symptoms in a number of genetically
 predisposed individuals (26,164).
 Measures of Heme Synthesis
 as Biological Markers
 of Chemical Exposure
 Measurements of the status of heme
 synthesis, particularly measurements of
 excreted heme precursors, have potential
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 field and clinical utility as biological
 indicators of chemical exposure and chemi-
 cal effect on body functions (98,165). This
 is well illustrated by the extensive experi-
 ence with lead, where measurements of
 protoporphyrin in blood [e.g., free erythro-
 cyte protoporphyrin (FEP) and ZPP] and
 ALA and coproporphyrin in urine have
 been used, and in the case of ZPP are still
 used, as sensitive markers of lead intoxica-
 tion. Animal experiments have demon-
 strated that a number of metals produce
 characteristic patterns of change in the uri-
 nary excretion of heme precursors, that the
 induced disturbances in heme synthesis are
 typically associated with ultrastructural
 changes and alterations of other subcellular
 processes, and that these measurable changes
 occur before the effects of metal exposure
 would be clinically evident (98,161).
 Therefore, measurements of heme precur-
 sors may offer a means of detecting harm-
 ful effects of specific chemical exposures
 in humans at stages of biological response
 to exposure that are still preclinical and
 are presumably most reversible. As the pre-
 ceding sections indicate, however, only a
 small number of studies in humans have
 attempted to assess the utility and validity
 of heme precursor measurements or other
 measures of the status of heme synthesis as
 markers of exposure or preclinical disease in
 chemically exposed humans.
 Unexplained Chemical-
 associated Illnesses
 and Measures of
 Heme Synthesis
 It has recently been proposed that a variety
 of chemical-associated illnesses for which
 there are no widely accepted specific diag-
 nostic tests or etiologic explanations-such
 as MCS syndrome, Persian Gulf War ill-
 nesses, conditions associated with silicone
 breast implants, and various fatigue syn-
 dromes-may represent either mild chronic
 cases of porphyria, or at least in part, mani-
 festations of acquired abnormalities in
 heme synthesis (166-177).
 The MCS syndrome (178-180) has
 been defined by Cullen (181) as "an
 acquired disorder characterized by recur-
 rent symptoms, referable to multiple organ
 systems, occurring in response to demon-
 strable exposure to many chemically unre-
 lated compounds at doses far below those
 established in the general population to
 cause harmful effects." No physiologic test
 has been widely accepted as correlating
 with symptoms in MCS syndrome,
 although a variety of immunologic and
 n urologic tests have been described as
 abnormal or diagnostic based on clinical
 series data. Of note, however, one blinded
 prospective controlled study evaluated a
 panel of immunologic tests offered by a
 laboratory with recognized interest in the
 evaluation of individuals with chemical
 sensitivities, and found that the tests did
 not distinguish between MCS patients and
 control patients (182). Still, in spite of
 continued debates about the origins of
 MCS syndrome, there is little doubt that it
 can b  associated with substantial sympto-
 matic distress, major lifestyle disruption,
 and severe degrees of inability to perform
 usual activities of work and daily life.
 To date, the hypotheses of porphyric
 mechanisms in these otherwise unex-
 plained syndromes are based only on indi-
 vid al cases or case series characterized by
 relatively mild increases in porphyrin
 excretion and/or decreases in activity of
 various heme-synthesis enzymes. The data
 reported to date have not identified any
 characteristic unifying pattern(s) among
 the l boratory test results. Donnay and
 Ziem (171) reported in 1995 that two
 medical practices in Washington State had
 found excess porphyrins and/or enzyme
 abnormalities in patterns that did not
 match those of any inherited porphyrias in
 over 70% of more than 150 MCS patients
 with symptoms of porphyrinopathy.
 Morton (172) described laboratory find-
 ings for 38 individuals with chemical sensi-
 tivities and deficient activity of at least 1 of
 5 tested heme-synthesis enzymes. Although
 he did not distinguish between the mar-
 ginal and low laboratory reference ranges
 in defining deficiency (see "Limitations of
 Laboratory Measures of Heme Synthesis"),
 22 (58%) had deficiency of coproporphy-
 rinogen oxidase (Copro-O), 13 (34%) had
 deficiency of protoporphyrinogen oxidase,
 and 27 (71%) had at least 1 excess por-
 phyrin in feces or urine (values reported
 only as yes or no). Of note, 7 of the 22
 individuals with Copro-O deficiency and 4
 of the 16 individuals with deficiency of
 enzymes other than Copro-O had no
 detected excess of porphyrins in feces or
 urine. Ziem and McTamney presented
 supporting clinical data at a recent scien-
 tific meeting; those data are not yet avail-
 able for circulation (177).
 Downey (168) described hereditary
 coproporphyria in 13 patients (plus 7 family
 members) who arrived at an oral stomatol-
 ogy clinic with unexplained oral conditions
 and multiple systemic complaints: 16 of 19
 tested had abnormal Copro-O activity, 3
 of those 16 had one other abnormal heme-
 synthesis enzyme, and 14 of 14 tested had
 elevated heme precursors in urine or stool.
 Of the 16 abnormal Copro-O activity val-
 ues, 14 were in the marginal reference
 range (0.06-0.09 relative units) and the
 other 3 values were just below the marginal
 range (0.05 relative units) (182). Of the 21
 elevated heme precursor values (most often
 coproporphyrin), 17 (81%) were 1.1 to 1.8
 times higher than the respective value
 reported for the upper limit of normal, and
 4 (2 in stool and 2 in urine) were 2.0 to
 2.3 times higher (182). Downey (167)
 entioned that about 90% of 62 patients
 (including the above-described 19) were
 found to have one or more heme-synthesis
 enzyme abnormalities.
 Two types of hypotheses have been put
 forth in explanation of such laboratory
 f dings occurring with otherwise unex-
 plained chemical-associated illnesses. The
first hypothesis is that these illnesses are
actually porphyrias, in which illness is pre-
 cipitated by environmental chemical expo-
 sures in genetically predisposed individuals
 (160,167,172). Proponents suggest that the
 latent genetic traits for various porphyrias
 are much more common in the general
 p pulation but were not recognized until
 the recent increased availability of labora-
 tory assays for the activity of heme-synthesis
 enzymes. It is hypothesized that such genet-
 ically predisposed individuals can manifest
 porphyria symptoms in low-grade smolder-
 ing or chronic and slowly progressive pat-
 terns (without classically recognizable acute
 attacks of severe symptoms) in response to
 exposures to a variety of substances such as
 "f rmaldehyde, other aldehydes, heavy
 vehicle exhaust fumes, perfumes, other fra-
 grances, chlorine, chlorinated cleaning
 agents, possibly any chlorinated hydrocar-
 bon  substances in poorly ventilated build-
 ings, and anything that triggers porphyria
 symptoms" (172). It is contended that these
 chronic symptom patterns are not necessar-
 ily accompanied by diagnostic abnormali-
 ties of heme precursors, possibly because a
 "limited attack especially on a small num-
 ber of cells or on cells where the heme path-
 way is not a major functioning system or
 where the affected cells do not have ready
 access to external excretory processes may
 not raise porphyrin precursors above nor-
 mal levels" (167); measurement of heme-
 synthesis enzyme activities, therefore, is
 regarded as critical to diagnosis.
 The second hypothesis is that genetic
 predisposition may not be an essential
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 component of a porphyric mechanism
 in MCS syndrome, and that reported
 reductions in activity of heme-synthesis
 enzymes might represent an acquired defi-
 ciency attributable to exogenous toxic
 agents or stressors, manifesting as either
 an intoxication porphyria or some other
 as-yet undefined disorder of porphyrin
 metabolism (169,171). It is hypothesized
 that "the heme pathway may be just one
 of many sites in the body adversely
 affected by exposure to toxic chemicals,
 and that this interaction could account for
 many of the cutaneous, neurological and
 psychological symptoms reported by MCS
 patients, including the most controversial
 symptom of chemical sensitivity itself"
 [A Donnay, personal communication;
 (166)]. Some cases of MCS syndrome are
 predicted to be porphyric and the others
 nonporphyric (171).
 Limitations of
 Laboratory Measures
 of Heme Synthesis
 In evaluating the symptomatic patient
 with a suspected disturbance of the heme
 synthesis pathway, the interpretation of
 laboratory tests must consider the condi-
 tions of sampling and the limitations of
 those tests.
 Methodologic Limitations
 Laboratory test results, in general, can be
 compromised by a variety of factors,
 including specimen integrity (reflecting
 conditions of specimen collection, process-
 ing, transport, and storage), analytical
 quality, limitations of analytical methods,
 and the applicability and specificity of ref-
 erence ranges, including the range of nor-
 mal intraindividual variability. Issues of
 specimen integrity may be particularly rele-
 vant when specimens are collected and
 processed at one site and then transported
 to a geographically distant reference labora-
 tory, as in nearly all the cases described in
 "Unexplained Chemical-associated Illnesses
 and Measures of Heme Synthesis." Speci-
 men integrity is a particular concern in
 enzyme activity assays. There is the risk of
 obtaining falsely low measurements of
 enzyme activity because of the potential
 lability of enzymes after removal from the
 body. Because of these risks, an abnormal
 test result generally should be confirmed by
 analysis of a second specimen. The need to
 repeat a test, of course, must be tempered
 by the degree of support for a diagnosis
 from other clinical and laboratory data,
 and by the feasibility of repeating the test
 (i.e., the appropriate clinical circumstances
 should still be present).
 Reference Ranges
 In add tion to considering methodologic
 limitations, the interpretation of any labo-
 rat ry test should consider potential limita-
 tions of the test reference range. First,
 reference ranges usually do not include all
po sible values for normal people (184).
 It is common laboratory practice to define
 a reference range as the mean ? 2 SD,
 based n the distribution of test results in
 an ostensibly normal reference sample;
 therefore, it is expected that 5% of normal
 individuals, and possibly more if the distri-
 bu ion is skewed, will have low or high
 outly ng values. Second, the range of possi-
 ble test values may overlap for normal and
 affected individuals, and many tests might
 be more appropriately characterized as hav-
 ing an inconclusive range or a continuum
 between normal and diagnostic ranges,
 rather than simply being dichotomized
 (185-187). Third, the usual ranges of test
 values for normal individuals and for indi-
 viduals with a given disease may differ so
 substantially that intermediately abnormal
 values might be regarded as nondiagnostic
 for that disease.
 It is particularly important to recognize
 that there can be considerable normal
 intraindividual variation in physiologic
 tests (183); often for specific tests either
 this has not been characterized or the
 degree of expected variability has not been
 made known to the clinician. Any such
 variation, however, can limit the clinician's
 ability to interpret a test result confidently
 as abnormal when an individual's single
 result is outside the reference range by an
 amount that is small relative to expected
 intraindividual variability on that test. One
 study, for example, reported a 3-fold differ-
 ence between the highest and lowest total
 porphyrin measurements in 24-hr urine
 specimens (normally comprised mostly of
 coproporphyrin) collected over 7 consecu-
 tive days from the same person; all values
 were normal except one that exceeded the
 value reported for the upper limit of normal
 by about 25% (131).
 Finally, because a reference range may
 be unique to the assay method and the lab-
 oratory performing the test, test results
 should be interpreted relative to the labora-
 tory-specific reference range and/or, if suf-
 ficient general clinical experience exists,
 against accepted absolute reference stan-
 dards. However, a reference range may have
 limited representativeness for test subjects,
 even when derived from a large sample of
 normal individuals, if test subjects differ
 from the reference sample in terms of the
 circumstances affecting specimen integrity
 or in terms of potentially confounding per-
 sonal factors. For example, the study of
 PBB-exposed Michigan farm families (see
 "Environmental Chemicals and Effects on
 Measures") found total urine porphyrins
 were significantly higher on average than
 those in the Dutch reference sample, but
 they were no different than those in a
 contemporary control group of Wisconsin
 farm families (131).
 Enzyme Activity Measurements
 The diagnostic value of activity measure-
 ments for heme-synthesis enzymes depends
 on the presence or absence of symptoms
 and on other clinical and laboratory data,
 particularly the level and pattern of any
 associated overproduction of heme precur-
 sors. Individuals who are genetically predis-
 posed to a porphyria usually will have
 deficient activity of the associated enzyme,
 yet a substantial proportion will never
 develop symptoms of a porphyria. There-
 fore, identification of the genetic trait alone
 in a symptomatic patient is not by itself
 sufficient evidence of symptom causality.
 In addition, reductions in enzyme activity
 do not necessarily reflect a genetic trait;
 certain exogenous agents such as alcohol or
 lead can inhibit or interfere with the activ-
 ity or alter the synthesis of specific enzymes
 in the heme synthesis pathway (11,74).
 Conversely, normal enzyme activity mea-
 surements can reduce the likelihood,
 a though they do not completely eliminate
 th  possibility, that a person has porphyria.
 There is typically a substantial degree of
 overlap in enzyme activity values for nor-
 mal individuals and for individuals with a
 porphyria characterized by deficiency in
 hat enzyme (73,188). Also, some porphy-
 rias do not necessarily manifest the associ-
 ated enzyme deficiency in erythroid cells,
 even though it may be present in other tis-
 sues (e.g., variant AIP, when a mutation is
 in or near exon 1 of the PBG deaminase
 gene and affects only the nonerythroid
 enzyme) (10).
 The measurement of specific heme-
 synthesis enzyme activities is commonly
 considered a second-line test in the evalua-
 tion of porphyrias (189). Enzyme activity
 measurements are most often used for iden-
 ifying a genetic trait for porphyria in fam-
 ily members of a person with diagnosed or
 suspected porphyria to identify individuals
 who should be counseled on the need to
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 minimize or avoid exposure to factors
 known to precipitate porphyria, even
 though they may have been asymptomatic
 to date (7,188,190,191). Enzyme activity
 measurements also can be useful when a
 symptomatic person is diagnosed as having
 a porphyria of some type-based on symp-
 tom pattern and a substantial increase in
 excretion of heme precursor(s)-but the
 pattern of heme-precursor excretion does
 not allow differentiation of the specific
 type of porphyria; proof of deficient activ-
 ity for a specific heme-synthesis enzyme
 can facilitate determination of the specific
 porphyria. Measurements of enzyme
 activity otherwise have limited utility in
 the evaluation of suspected porphyria in
 symptomatic individuals.
 Coproporphyrinogen Oxidase Activity
 Decreased Copro-O activity is the most
 frequently identified enzyme finding, and
 in many cases is the sole basis for diagnos-
 ing a disturbance of heme synthesis in the
 above-mentioned cases of unexplained
 chemical-associated illnesses with reportedly
 abnormal measures of heme synthesis (see
 "Unexplained Chemical-associated Illnesses
 and Measures of Heme Synthesis").
 The assay for Copro-O activity is the
 subject of some controversy. At present,
 only one laboratory offers a Copro-O activ-
 ity assay on a commercial basis. That assay
 is performed by the incubation of ALA
 substrate with a lysed peripheral blood cell
 specimen, followed by analysis of the por-
 phyrins formed; a low yield of protopor-
 phyrin and a normal or increased yield of
 coproporphyrins indicate a deficiency of
 Copro-O (183). The commercial assay,
 therefore, uses coproporphyrinogen synthe-
 sized enzymatically in situ from ALA added
 to the incubate. In contrast, research labo-
 ratories that perform Copro-O activity
 assays in peripheral blood cells do so in iso-
 lated leukocyte or lymphocyte fractions,
 using externally synthesized coproporphy-
 rinogen as specific substrate (16,192-194).
 It is widely believed that heme synthesis
 in humans is confined to nucleated cells
 and that Copro-O is a mitochondrial
 enzyme. However, there is little published
 information that addresses the relative
 degrees of Copro-O activity in reticulo-
 cytes, mature erythrocytes, and leukocytes
 (16,195,196). Heme synthesis in periph-
 eral blood cells is expected to occur only in
 leukocytes and perhaps in reticulocytes,
 and not in mature erythrocytes, which lack
 nuclei and mitochondria and which consti-
 tute about 99% of peripheral blood cells.
 Mitochondria are present in nucleated
 blood cells but are not normally present in
 ure erythrocytes. Developers of the
 lysed-blood assay maintain, however, that
 circulating erythrocytes can transform 10 to
 40% of available coproporphyrinogen III to
 protoporphyrinogen during 3-hr incuba-
 tions, with reticulocytes having at least
 twice as much Copro-O activity as older
 erythrocytes, and with overall erythrocyte
 activity far exceeding that seen in lympho-
 cytes (RD Ellefson, personal communica-
 tion). The subcellular distribution of the
 reported Copro-O activity in erythrocytes is
 unclear; remnants of mitochondria are one
 speculated possibility.
 It is generally agreed that because the
 percentage of reticulocytes varies among
 normal persons and can change dramati-
 cally in a number of disease states, interpre-
 ation of test values from the lysed-blood
 assay should at least be adjusted for the
 reticulocyte count (183). It is also agreed
 that regardless of the technique used to
 assay activity, Copro-O is a particularly
 labile enzyme after removal from the body.
 Vigorous specimen processing or failure to
 properly maintain the specimen during
 transport or storage can cause enzyme
 damage and produce falsely low (i.e., false
 positive) test results (183).
 Evaluating the Symptomatic
 Patient in Whom Porphyria
 Is Suspected
 The most important first step toward
 diagnosing or ruling out porphyria in a
 symptomatic patient is for the clinician to
 maintain a high index of suspicion for a
 possible diagnosis of porphyria, whether
 symptoms are classic for a porphyria or are
 vague or unexplained. The conclusive diag-
 nosis of a porphyria should be based on a
 systematic approach incorporating medical
 history, physical examination, and biochem-
 ical data, and including genetic evaluation if
 necessary. Certain symptom patterns, physi-
 cal findings, and elements of the exposure
 history may raise the degree of suspicion for
 porphyria; however, the lack of supporting
 information from these sources cannot
 exclude a diagnosis of porphyria. Therefore,
 the systematic approach to evaluating a
 symptomatic patient with suspected por-
 phyria must include laboratory evaluation
 (see also "Biochemistry of Porphyrias").
 Laboratory Evaluation-
 Diagnosis of Porphyria
 The nature and pattern of a patient's
 ymptoms and physical signs may provide
 some guidance in the selection of tests for
evaluating the symptomatic patient with
 suspected porphyria. However, the neuro-
 logic and cutaneous manifestations of por-
phyrias can be nonspecific or atypical and
caution is necessary to avoid being overly
 focused on the basis of clinical appearance
 in initial test selection. Reviewers make
 slightly different recommendations regard-
 ing the appropriate panel of first-line tests
 for the evaluation of suspected porphyria.
 The most common recommendation-
 when symptoms suggest possible neurologic
 manifestation(s) of an acute porphyria-is
 for the measurement of PBG with or with-
 out ALA in urine (46,52,54,189). Most
 reviewers also recommend quantification of
 total or individual porphyrins in urine and,
 routinely or supplementally, in stool-par-
 ticularly when symptoms or signs suggest
 possible cutaneous manifestations of por-
 phyria. Measurement of protoporphyrin in
 blood is often recommended, depending
on the degree of suspicion for erythropoietic
 protoporphyria. Anderson (10) alterna-
 tively recommends measurement of total
plasma porphyrins, plus urine PBG and
 ALA, to determine the presence or absence
 of porphyria. A blood lead level, with or
 without a ZPP level, should also be consid-
 ered because of the similarity of symptoms
 in lead poisoning and porphyrias with
 neurologic manifestations.
 It is generally less difficult to determine
 whether a patient has porphyria than it is
 to differentiate which specific type of por-
 phyria is present. The presence or absence
 of increases in urinary ALA and PBG and
 the relative increases in the individual por-
 phyrins are particularly helpful in diagno-
 sis. The nature and pattern of reported
 symptoms can assist in differentiation. The
 cited general references and review articles
 (1-10,46,52,54,189) provide information
 regarding the patterns of laboratory abnor-
 malities to consider in attempting to differ-
 entiate the specific type of porphyria in the
 patient who has laboratory and clinical evi-
 dence consistent with a porphyria. We will
 not discuss further this level of differential
 diagnosis; we will focus on preliminary
 screening steps in the diagnostic evaluation
of a possible porphyria.
 Laboratory Evaluation-
 Excluding Porphyria
 as the Cause of Symptoms
 As discussed in "Biochemistry of Porphyrias,"
 when a porphyria (or another clinically
 important disturbance of heme synthesis,
 .g., lead intoxication) of any recognized
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 type is symptomatic, it is almost always
 accompanied by substantial overproduction
 and increased excretion of heme precursors,
 typically at least several-fold greater than
 the value reported for the upper limit of
 normal. One possible but infrequent excep-
 tion occurs after a patient with acute por-
 phyria develops a neurologic deficit that
 becomes permanent while the porphyria
 is otherwise in remission; biochemical
 parameters may return to normal ranges.
 Conversely, in a patient who is cur-
 rently or recently symptomatic and who is
 suspected to have a porphyria, it is not
 probable that the patient's symptoms are
 attributable to a porphyria of any type
 unless a measurement on at least one of the
 following tests is greater than twice the
 value reported for the upper limit of nor-
 mal: ALA, PBG, uroporphyrin, or copro-
 porphyrin in urine; blood total porphyrins;
 or fecal coproporphyrin (see "Biochemistry
 of Porphyrias") (90,189). A blood lead level
 should be checked to determine the possi-
 bility of lead intoxication if lead exposure
 is possible, if excretion of coproporphyrin
 or ALA is increased, or if blood porphyrins
 (e.g., ZPP) are increased. If a person is cur-
 rently or recently symptomatic and has
 reduced activity of a specific heme-synthe-
 sis enzyme, but laboratory testing does not
 reveal overproduction of heme precursors
 in a pattern and levels consistent with the
 porphyria associated with deficiency of that
 enzyme, then the reduction in measured
 enzyme activity has no probable causative
 relationship to the person's symptoms.
 Satisfaction of these 2-fold-threshold
 screening criteria does not necessarily estab-
 lish a diagnosis of porphyria. Depending on
 the degree and pattern of abnormalities on
 these tests, additional testing may be neces-
 sary to establish or exclude a diagnosis of
 porphyria. It is possible that an individual
 could have an abnormal heme-precursor
 measurement with this degree of abnor-
 mality as a consequence of something other
 than porphyria (or lead intoxication).
 Other medical conditions can cause sec-
 ondary porphyrinuria of this magnitude.
 Blood porphyrins can also be increased
 by this magnitude in conditions other
 than porphyria; for example, iron defi-
 ciency commonly produces an increase in
 blood ZPP.
 Conversely, failure to satisfy these
 2-fold threshold-screening criteria does not
 necessarily exclude a diagnosis of por-
 phyria. Heme-precursor measurements in
 the range of one to two times the value
 reported for the upper limit of normal
 should not be interpreted as normal but
 rather as indeterminate or nondiagnostic.
 The timing of sample collection relative to
 the occurrence of symptoms is critical.
 When a patient with suspected porphyria is
 not currently or recently symptomatic, the
 levels of heme-precursor excretion are gen-
 erally lower and can even normalize with
 time (i.e., within days to weeks). If a
 patient's last symptoms occurred remotely
 in the time relative to specimen collection,
 it may be necessary to repeat the tests dur-
 ing or as soon as possible after future symp-
 t ms. In view of expected interindividual
 variations and the potential processing and
 analytic limitations of laboratory tests, par-
 ticularly at the low range of abnormality,
mildly abnormal levels of heme-precursor
 excretion generally should be repeated
 before utilizing them as justification for
 further diagnostic assessment.
 Secondary Porphyrinurias
 Indeterminate or nondiagnostic levels of
 porphyrin excretion might represent a sec-
 ondary porphyrinuria. With the note-
 worthy exception of lead poisoning, the
 porphyrin excess in secondary porphyrin-
uria has no recognized clinically detectable
 consequences of its own. Medical condi-
 tions that appear to have only secondary
 effects on the heme synthesis pathway
are appropriately evaluated, with atten-
 tion focused on the primary condition.
 Similarly, when chemical exposures are sus-
 pected as the cause of a patient's symptoms
 or medical condition, the exposure rela-
 tionship can be characterized more speci-
 fically by exposure assessment or by
 quantification of the suspected chemical
 (or its metabolite) in blood or urine than
 by measurement of heme precursors. Lead
 poisoning, for example, is probably the
 most commonly recognized condition that
 can result from a chemical exposure and
 that is accompanied by abnormal measures
 of heme synthesis. However, even though
 these measures provide sensitive indicators
 of lead exposure and effect, the blood lead
 level is a more sensitive and more specific
 test for the diagnosis and management of
 lead poisoning.
 Exposure Relationships
 If it is ultimately determined that a
 symptomatic patient has a specific por-
 phyria or another clinically important dis-
 turbance of heme synthesis (e.g., lead
 intoxication) and if the possibility of expo-
 sure relationship or work relationship is at
 issue, then the exposure history and any
 independently available exposure data
 should be reviewed to assess the likelihood
 that an exogenous chemical(s) might have
 triggered or caused the diagnosed condi-
 tion. The potential complexity of the expo-
 sure assessment process is beyond the scope
 of this review. Exogenous agents that are
 known or suspected to cause or to trigger
 porphyria are discussed above. Given that
 there has been only limited systematic study
 of potentially porphyrinogenic chemicals in
 humans, however, consideration of possible
 exposure relationships should not be con-
 fined to chemicals known or suspected to
 affect heme synthesis.
 Conclusions
 There is little question that individuals
 who are genetically predisposed to a por-
 phyria can have clinical manifestations of
 porphyria triggered by exogenous chemicals.
 Most of the experience with such chemical
 triggering of porphyria has involved alco-
 hol consumption and pharmacological
 doses of drugs. However, other chemical
 exposures have also been reported to trig-
 ger porphyrias with neurologic manifesta-
 tions as well as those with only cutaneous
 manifestation-PCT in particular.
 It is also clear that certain exogenous
 chemical exposures can actually cause
 porphyria in the absence of genetic pre-
 disposition. This is demonstrated most con-
 vincingly by the Turkish epidemic of PCT
 caused by HCB intoxication. Other chemi-
 cals have also been linked to cases of porphy-
 ria in humans; the reported cases, however,
 have been infrequent, have all involved
 PCT, and have generally been linked to
 chronic industrial exposures, industrial acci-
 dents, or environmental exposures that
 were much higher than normally encoun-
 tered. Chemical exposures have not been
 established as a cause (i.e., not just a trigger
 in the presence of genetic predisposition) of
 porphyrias with primarily neurologic mani-
 festations, although lead intoxication is
 noteworthy as a possible exception.
 There is no doubt that lead absorption
 can cause substantial disturbance of heme
 synthesis. Lead intoxication has prominent
 manifestations as well as biochemical abnor-
 malities that mimic the manifestations of
 the neurologic porphyrias. It is not known
 to what degree the neurologic manifesta-
 tions of lead poisoning might be attribut-
 able (if at all) to the associated disturbance
 in heme synthesis, apart from the directly
 neurotoxic properties of lead, but there is
 evidence the disturbed heme-forming
 system may have some contributing role.
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 It must be acknowledged that there
 have been only a limited number of system-
 atic attempts to identify porphyria or even
 subclinical porphyrinuria in chemically
 exposed humans, and that a large number
 of chemicals have been identified as por-
 phyrinogenic in experimental animals-
 albeit with doses much greater than the
 usual range of human experience. In some
 cases, these effects result from inhibition of
 or interference with specific enzymes in the
 heme synthesis pathway; however, some of
 these effects can be produced by mecha-
 nisms that do not involve an abnormality
 in the heme-forming system. Regardless of
 the causative mechanism, these chemical-
 related changes have potential utility as
 biological indicators of chemical exposures
 that might have significant pathologic
 effects. There is a need for further research,
 including trial field applications, of such
 porphyrin biomarkers.
 Clinicians should maintain a reasonable
 degree of suspicion for the possibility of a
 disturbance in' heme synthesis underlying
 any unexplained syndrome characterized
 by nonspecific symptoms if even mildly
 reminiscent of porphyria, whether or not
 environmental chemical exposures are sus-
 pected as causative or contributing agents.
 However, heme-precursor measurements
 obtained when a patient is symptomatic
 should be interpreted cautiously and/or
 repeated if not substantially elevated (i.e.,
 at least 2-fold greater) relative to the respec-
 tive value reported for the upper limit
 of normal.
 With the noteworthy exceptions of lead
 intoxication and the porphyrias in clini-
 cally active states, the porphyrin excess
 associated with porphyrinurias has no
 known clinically detectable consequences
 of its own. Symptoms associated with such
 secondary porphyrinurias are attributed by
 most reviewers to the condition or agent
 causing the porphyrinuria or to an unre-
 lated cause and not to a disturbance in
 heme synthesis. Such porphyrinuria may
 be relevant as a nonspecific laboratory indi-
 cator of some other operative pathophysio-
 logic mechanism, much as an elevated
 sedimentation rate can provide contribu-
 tory but nonspecific evidence of disease;
 however, it is most appropriate for further
 diagnostic attention to focus on the pri-
 mary condition or exposure of concern,
 not necessarily on a mild disturbance of
 heme synthesis.
 A variety of chemical-associated illnesses
 with unknown causative mechanisms,
 notably MCS syndrome, have been reported
 in association with abnormal results of
 porphyria-related tests. It is hypothesized
 that these test values reflect pathophysio-
 logic disturbances of heme synthesis that
 are directly involved in the manifestation
 of those illnesses. Proponents of these
 hypotheses point out that many MCS
 symptoms resemble the neurologic and
 cutaneous manifestations of porphyrias.
 Yet, cutaneous symptoms are usually not a
major feature of MCS syndrome, and
 when present, they differ substantially
 from the cutaneous manifestations of the
 inherited and acquired porphyrias. The
 noncutaneous symptoms of MCS syn-
 drome are much less intense and less
 discretely episodic than the common neu-
 rologic manifestations of porphyrias. The
 clin al course of porphyrias with neuro-
 logic manifestations can, as with MCS syn-
 drome, occur in a chronic or indolent
 pattern, and does not occur exclusively
 as acute symptom attacks separated by
 symptom-free intervals; however, in the
 neurologic porphyrias, in contrast to MCS
 syndrome, the chronic pattern occurs
 much less frequently than the pattern of
 acute symptom attacks.
 Proponents of porphyric hypotheses for
 MCS syndrome point out another similar-
 ity with the porphyrias-the propensity for
 symptoms to be caused or triggered by
 exogenous chemical exposures. However,
 the very low levels of exposure to which
 MCS patients are characteristically sensitive
 are much lower than the pharmacological
 doses of drugs that are known to trigger
 neurologic symptoms in genetically predis-
 posed individuals. These levels are also
 much lower than the chemical exposures
 reported to date in association with PCT or
 subclinical porphyrinurias in humans,
 where situations generally have involved
 chronic industrial exposures, industrial acci-
 dents, or environmental exposures that
 were much higher than normally encoun-
 tered, and with the exception of lead intoxi-
 cation, have not been reported to involve
 low-level environmental exposures.
 It is conceptually difficult to reconcile
 why MCS syndrome, if mediated substan-
 tially through a disturbance in heme syn-
 thesis, would have a markedly greater
 degree of chemical intolerance and greater
 frequency of chronic functional limitations
 than recognized forms of prophyria but
would never manifest symptoms or signs as
 severe as can occur with porphyrias, and
 would have markedly lower or even absent
 elevations of heme-precursor excretion
 when symptomatic compared to porphyria
 patients when symptomatic. One contention
 is that circumscribed disturbances of heme
 synthesis (i.e., limited to a small number of
 cells) can cause symptoms without produc-
 i g measurable or substantial increases in
 heme precursors and that heme-synthesis
 enzyme measurements, therefore, are the
 more critical, if not the only necessary,
 diagnostic measure. Although it is well rec-
 ognized that heme synthesis can be dispro-
 portionately affected in different organ
 s stems with any one type of porphyria, it
 is contrary to other clinical evidence to
 date (with rare exceptions) that a distur-
 bance of heme synthesis is so profound as
 to produce symptoms without also produc-
 ing substantial elevations of heme precur-
sors. Similarly, there is no other evidence
 t  date that a heme-synthesis enzyme
with low activity, particularly when mar-
 ginal activity values are overinterpreted as
 low, can be linked to symptoms without
 an accompanying substantial increase in
 heme precursors.
 It is sometimes contended in individual
 ca es that the timing of specimen collection
 was not sufficiently close in time to a symp-
 tom episode to depict the full degree of
 heme-precursor abnormalities associated
 with that individual's symptoms. Although
 the biochemical abnormalities of some por-
 ph rias may return to normal ranges during
 p iods of clinical remission, such normal-
 ization generally requires at least several
 days or weeks, if it occurs at all. Given the
 typical frequency of symptom episodes in
 individuals with MCS syndrome, and if a
 disturbance of heme synthesis is an opera-
 tive pathophysiologic mechanism, the tim-
 ing of specimen collection should not be
 an issue.
 To date, the efforts to relate MCS
 syn rome and other unexplained chemical-
 associated illnesses to disturbances of heme
 synthesis have all involved selected case
 series with no consistent or stated case defi-
 nitions, using only laboratory reference
 ranges for comparisons, and with little or
 no attention to the methodologic and
 interpretive limitations of measures of
 heme synthesis. Based on the limited exist-
 ing data, it is reasonable at least to consider
 he possibility that there might be a higher
 than previously recognized prevalence of
 ab ormalities in measures of heme synthe-
 sis among patients with MCS syndrome.
 However, to date there is no convincing
 evi ence that there is-or is not-any
 uch increased prevalence of abnormal
 measures of heme synthesis associated with
 MCS syndrome. Given the current paucity
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 of evidence in favor of disturbances of
 heme synthesis being operative in MCS
 syndrome and other unexplained chemical-
 associated illnesses, and unless supportive
 evidence can be provided by well designed
 and controlled studies, the proposed
 relationships with disturbances of heme
 synthesis should, at most, be considered
 speculative and unestablished. In cases
 involving these otherwise unexplained ill-
 nesses, and when there is no demonstrable
 substantial accumulation or increased
 excretion of heme precursors, it is premature
 or unfounded either to apply a diagnosis of
 porphyria (or any less defined pathologic
 disturbance of heme synthesis) or to use
 such diagnoses as specific justification for
 lifestyle alterations or therapeutic interven-
 tions; porphyria-specific interventions,
 such as intravenous hematin, should not be
 recommended in such instances.
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